RegionInternational. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  PTD-DBM
Research reference — not for sale

PTD-DBM

F
lead outcome
Human evidence for hair growth
grades vary by outcome ↓
Peptide
also called — PTD-DBM · Dishevelled-binding motif peptide (CXXC5 inhibitor) · protein-transduction-domain DBM peptide · INCI: none
hair growth (preclinical)Wnt/β-catenin activation (CXXC5 inhibition)

Reference entry — not sold here. A Wnt-activating hair-growth peptide with coherent mechanism and mouse-only, often-combination data. No human trials. No dosing published here.

In brief

PTD-DBM is a synthetic peptide designed to switch on Wnt/β-catenin signalling — a core hair-follicle growth pathway — by blocking CXXC5, a protein that normally puts the brakes on it. In mouse studies (largely from Korean groups, and often combined with valproic acid) topical PTD-DBM promoted hair regrowth, which is why it circulates as a research hair-loss peptide. The target is genuinely interesting and mechanistically coherent. But the evidence is preclinical, concentrated in the originating labs, frequently in combination rather than alone, and there are no human studies of any kind. An intriguing hair-growth hypothesis with mouse-only data.

Legal standing, by region
European Union
Not approved

No marketing authorisation; not an authorised cosmetic or drug ingredient. Research chemical only.

United States
Not FDA-approved

Not FDA-approved; not a supplement; no clinical trials registered.

International
Approved nowhere

Approved in no jurisdiction for any indication.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Human evidence for hair growth
Any topical "research" use is extrapolated from mouse studies, not a validated human protocol.
None. No published or registered human clinical trial of PTD-DBM for hair loss; no human efficacy or safety data. · Nothing demonstrated in humans.
F
Hair regrowth in mouse models (the lead claim)
Preclinical, concentrated in the originating groups, and frequently in COMBINATION with valproic acid — attribution to PTD-DBM alone is limited.
A widely cited mouse study (Korean groups) reported that topical PTD-DBM, which disrupts the CXXC5-Dishevelled interaction to release Wnt/β-catenin signalling, promoted hair regrowth — often studied together with valproic acid. · Reported hair regrowth in mice.
C
CXXC5-Dishevelled disruption / Wnt activation (mechanism)
Grades the mechanism. Wnt activation is a genuine hair-follicle pathway, but de-repressing a growth pathway also raises theoretical proliferative concerns, and mechanism in models is not a human outcome.
CXXC5 is a negative feedback regulator of Wnt/β-catenin; PTD-DBM is designed to block the CXXC5-Dishevelled interaction, de-repressing Wnt signalling that drives hair-follicle regeneration. · Coherent, specifically articulated mechanism.
C
Safety
Topical delivery limits systemic exposure, but no human safety characterisation exists; gray-market identity/purity risks apply.
No human data · Unknown in humans.
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for PTD-DBM changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

The honest part

PTD-DBM targets a real hair-follicle pathway (Wnt, via CXXC5 inhibition) and has a genuine mouse regrowth signal — but that signal is single-source, frequently produced in combination with valproic acid rather than alone, and has never been tested in a human. De-repressing a growth pathway also warrants caution. Interesting target; mouse-stage evidence.

Identity

PTD-DBM is a synthetic peptide combining a protein-transduction domain (PTD) — a sequence that helps it cross cell membranes — with a Dishevelled-binding motif (DBM). It is studied as a topical hair-growth agent, which places it at the edge of the cosmetic/therapeutic border even though it is sold as a research chemical.

Mechanism (as proposed)

The target is the Wnt/β-catenin pathway, a central driver of hair-follicle regeneration. A protein called CXXC5 acts as a negative feedback brake on that pathway by binding Dishevelled. PTD-DBM is designed to block the CXXC5-Dishevelled interaction, lifting the brake and letting Wnt signalling run — which in follicle biology favours regrowth. The logic is disinhibition, much like several other compounds in this register: don't push the accelerator, remove the brake. The mechanism is coherent and the pathway is real. Two honest qualifiers: releasing a growth pathway raises theoretical proliferative concerns, and pathway activation in a model is not a demonstrated human result.

Reading the evidence honestly

The regrowth evidence is mouse-stage and concentrated in the originating (largely Korean) groups, and a great deal of it pairs PTD-DBM with valproic acid, another Wnt activator — so the effect attributable to PTD-DBM alone is harder to isolate than the headlines suggest. There are no human studies of any kind. That combination of a real target, a single-source animal signal, frequent co-treatment, and zero human data is exactly what a D grade is for: genuinely interesting, nowhere near established.

Sources — 2 cited
01Lee SH, Choi BY, et al. (Topical PTD-DBM disrupting CXXC5-Dishevelled to activate Wnt/β-catenin and promote hair regrowth in mice — often with valproic acid.)
02Reviews of CXXC5 as a Wnt negative-feedback regulator and its role in hair- follicle regeneration.
Updated 2026-08-07 (No human trial registered — re-check for any first-in-human hair-loss study.)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
GHK-Cu Peptide (Copper Tripeptide-1)B
Peptide
Explore by goal
Hair & topical
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

RegionInternational
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen data
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.